Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Contrast-induced nephropathy Stories

2013-04-17 14:27:14

Contrary to the positive findings of a previous pilot study, administration of a sodium bicarbonate-based infusion to induce urinary alkalinization during and after surgery does not reduce the incidence of acute kidney injury (AKI) and may even cause harm in patients undergoing open heart surgery. These are the conclusions of a study by Anja Haase-Fielitz of the Otto-von-Guericke-University in Magdeburg, Germany, Rinaldo Bellomo of the Austin Hospital in Melbourne, Australia, and...

2012-08-13 02:25:50

MILFORD, Mass., Aug. 13, 2012 /PRNewswire/ -- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced that its innovative product, RenalGuard(®), was demonstrated at SOLACI 2012, the annual meeting of the Latin American Society of Interventional Cardiology, August 8-10, 2012, in Mexico City, Mexico. Girlow USA, PLC's distributor in Latin America for all countries with the exception of Brazil, exhibited RenalGuard in its booth at the...

2012-07-02 02:24:08

MILFORD, Mass., July 2, 2012 /PRNewswire/ -- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced that it has completed an additional round of financing with an affiliate of Genesis Capital Advisors LLC. These funds will enable PLC to continue its U.S. clinical trials for its RenalGuard® program, as well as continue to expand its distribution of RenalGuard internationally. PLC has received $1 million of the additional...

2012-05-11 02:23:39

MILFORD, Mass., May 11, 2012 /PRNewswire/ -- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced it will demonstrate its innovative product, RenalGuard(®), at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). More than 11,000 clinicians and medical professionals from around the world are expected to attend this event in Paris, France from May 15 - 18, 2012. In addition,...

2012-04-04 02:30:45

MILFORD, Mass., April 4, 2012 /PRNewswire/ -- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced that results from a new investigator-sponsored clinical trial of RenalGuard(R) in Italy -- the first to follow longer-term outcomes -- were presented at the annual conference of the American College of Cardiology (ACC.12), March 24 - 27, 2012, Chicago, Illinois. These results showed that RenalGuard is superior to two alternative methods...

2012-01-23 07:00:00

MILFORD, Mass., Jan. 23, 2012 /PRNewswire/ -- PLC Systems Inc. (OTC: PLCSF), a company focused on innovative medical device technologies, announced the successful enrollment of the first patient in the CIN-RG trial, the company's pivotal trial to study the efficacy of its RenalGuard Therapy® and RenalGuard System(TM) in the prevention of Contrast-Induced Nephropathy (CIN). This is an important step in the process to secure regulatory approval by the U.S. Food and Drug...

2012-01-13 07:00:00

MILFORD, Mass., Jan. 13, 2012 /PRNewswire/ -- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced that final results from the MYTHOS investigator-sponsored clinical trial of RenalGuard® in Italy have been published in the January 2012 issue of JACC - Cardiovascular Interventions, a peer-reviewed journal of the American College of Cardiology. The results from this trial showed that RenalGuard is superior to the current...

2012-01-05 15:05:00

MILFORD, Mass., Jan. 5, 2012 /PRNewswire/ -- PLC Systems Inc. (OTC: PLCSF), a company focused on innovative medical device technologies, announced today that Dr. Ichiro Michishita, a leading Japanese cardiologist, has successfully completed two cases utilizing RenalGuard® for the prevention of Contrast-Induced Nephropathy (CIN) at Yokohama Sakae Kyosai Hospital, Yokohama, Japan. This is the first step in the process to secure regulatory approval for RenalGuard in Japan. Dr. Michishita,...

2011-10-31 07:00:00

MILFORD, Mass., Oct. 31, 2011 /PRNewswire/ -- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that its new product, RenalGuard®, will be featured during Chronic Kidney Disease and Contrast Nephropathy, a 90 minute discussion session at Transcatheter Cardiovascular Therapeutics (TCT) 2011, November 7-11, 2011 in San Francisco, California. As part of its participation in this...

2011-10-14 07:00:00

MILFORD, Mass., Oct. 14, 2011 /PRNewswire/ -- PLC Systems Inc. (OTC: PLCSF), a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) to commence its U.S. pivotal trial to study the efficacy of the Company's RenalGuard Therapy® and RenalGuard System(TM) in the prevention of Contrast-Induced Nephropathy (CIN). Mark R. Tauscher, President and Chief Executive Officer of...